BobcatBio Email Format

Research ServicesPennsylvania, United States2-10 Employees

BobcatBio is a small biotechnology company in the research services industry, based in Hummelstown, Pennsylvania, with a team of 2-10 employees. It develops macrophage-based cell therapies for solid tumors, engineering autologous macrophages from a patient's blood without genetic modification and returning them to the patient. In preclinical studies, this approach has been shown to induce polyclonal tumor neo-antigen-specific killer T cell and antibody responses, resulting in complete resolution of treated tumors and the potential for lasting adaptive immunity against metastasis. Because the therapy does not target specific singular tumor antigens, the platform is modular and potentially applicable across multiple solid tumor types without pre-identification of target antigens. In March 2026, BobcatBio announced a strategic collaboration with Cellipont Bioservices to develop RB-1355, a cellular therapy that uses a patient's macrophages to elicit a targeted tumoricidal immune response. The company reports revenue in the range of $1M-$10M.

Get verified BobcatBio emails free

Company overview Employee directory